



FEP Medical Policy Manual

FEP 2.04.84 Measurement of Serum Antibodies to Selected Biologic Agents

Effective Policy Date: April 1, 2021

Original Policy Date: December 2013

Related Policies:

5.50.02 - Infliximab
5.50.12 Entyvio (vedolizumab)
5.70.29 Humira (adalimumab)
5.90.04 Stelara (ustekinumab)

Measurement of Serum Antibodies to Selected Biologic Agents

Description

Description

Biologic agents used to treat autoimmune diseases include infliximab, adalimumab, vedolizumab, and ustekinumab. Infliximab (Remicade) is an intravenous tumor necrosis factor α blocking agent approved by the U.S. Food and Drug Administration (FDA) for the treatment of rheumatoid arthritis, Crohn's disease, ankylosing spondylitis, psoriatic arthritis, plaque psoriasis, and ulcerative colitis. Adalimumab (Humira) is a subcutaneous tumor necrosis factor α inhibitor that is FDA approved for the treatment of Crohn disease and ulcerative colitis in adults and those with juvenile idiopathic arthritis. Vedolizumab (Entyvio) is an intravenous integrin receptor antagonist that is FDA approved for treatment of ulcerative colitis and Crohn Disease in adults. Ustekinumab (Stelara) is an intravenous and subcutaneous human interleukin-12 and -23 antagonist that is FDA approved for the treatment of psoriatic psoriasis, Crohn disease, and ulcerative colitis in adults, and plaque psoriasis in adolescents and adults. Following the primary response to these medications, some patients become secondary nonresponders. The development of antidrug antibodies is considered a cause of this secondary nonresponse.

OBJECTIVE

The objective of this evidence review is to evaluate and compare the net health outcome of 2 types of treatment: the first, when serum antibody testing for infliximab, adalimumab, vedolizumab, or ustekinumabis is used in patients being managed with those drugs; the second, when a patient receives standard of care to manage conditions (eg, rheumatoid arthritis, Crohn disease, ulcerative colitis) associated with the aforementioned drugs.

The policies contained in the FEP Medical Policy Manual are developed to assist in administering contractual benefits and do not constitute medical advice. They are not intended to replace or substitute for the independent medical judgment of a practitioner or other health care professional in the treatment of an individual member. The Blue Cross and Blue Shield Association does not intend by the FEP Medical Policy Manual, or by any particular medical policy, to recommend, advocate, encourage or discourage any particular medical technologies. Medical decisions relative to medical technologies are to be made strictly by members/patients in consultation with their health care providers. The conclusion that a particular service or supply is medically necessary does not constitute a representation or warranty that the Blue Cross and Blue Shield Service Benefit Plan covers (or pays for) this service or supply for a particular member.

POLICY STATEMENT

Measurement of antidrug antibodies in a patient receiving treatment with a biologic agent, either alone or as a combination test, which includes the measurement of serum TNF blocking agent levels, is considered **investigational**.

POLICY GUIDELINES

Currently U.S. Food and Drug Administration approved biologic agents include infliximab, adalimumab, vedolizumab, and ustekinumab.

BENEFIT APPLICATION

Experimental or investigational procedures, treatments, drugs, or devices are not covered (See General Exclusion Section of brochure).

FDA REGULATORY STATUS

Clinical laboratories may develop and validate tests in-house and market them as a laboratory service; laboratory-developed tests must meet the general regulatory standards of the Clinical Laboratory Improvement Amendments. Laboratories that offer laboratory-developed tests must be licensed by the Clinical Laboratory Improvement Amendments for high-complexity testing. To date, the U.S. Food and Drug Administration has chosen not to require any regulatory review of this test.

Prometheus Laboratories, a College of American Pathologists-accredited lab under the Clinical Laboratory Improvement Amendments, offers 4 non-radio-labeled, fluid-phase homogenous mobility shift assay tests: called Anser IFX (for infliximab), Anser ADA (for adalimumab), Anser VDZ (for vedolizumab), and Anser UST (for ustekinumab). The tests measure both serum drug concentrations and ADA. They are not based on an ELISA test, and can measure ADA in the presence of detectable drug levels, improving on a major limitation of the ELISA method..

RATIONALE

Summary of Evidence

For individuals who have rheumatoid arthritis, psoriatic arthritis, or juvenile idiopathic arthritis; inflammatory bowel disease (eg, Crohn's disease, ulcerative colitis); ankylosing spondylitis; or plaque psoriasis who receive evaluation for serum antibodies to infliximab, adalimumab, vedolizumab, or ustekinumab, the evidence includes multiple systematic reviews, a randomized controlled trial, and observational studies. Relevant outcomes are test validity, change in disease status, health status measures, quality of life, and treatment-related morbidity. , Antibodies to biologic agents develop in a substantial proportion of treated patients and are believed to neutralize or enhance clearance of the drugs. Considerable evidence has demonstrated an association between antidrug antibodies and secondary nonresponse as well as injection-site and infusion-site reactions. The clinical usefulness of measuring antidrug antibodies hinges on whether test results inform management changes, thereby leading to improved outcomes, compared with management directed by symptoms, clinical assessment, and standard laboratory evaluation. Limited evidence has described

The policies contained in the FEP Medical Policy Manual are developed to assist in administering contractual benefits and do not constitute medical advice. They are not intended to replace or substitute for the independent medical judgment of a practitioner or other health care professional in the treatment of an individual member. The Blue Cross and Blue Shield Association does not intend by the FEP Medical Policy Manual, or by any particular medical policy, to recommend, advocate, encourage or discourage any particular medical technologies. Medical decisions relative to medical technologies are to be made strictly by members/patients in consultation with their health care providers. The conclusion that a particular service or supply is medically necessary does not constitute a representation or warranty that the Blue Cross and Blue Shield Service Benefit Plan covers (or pays for) this service or supply for a particular member.

management changes after measuring antidrug antibodies. A small randomized controlled trial in patients with Crohn disease comparing antidrug antibody-informed management of relapse with standard dose escalation did not demonstrate improved outcomes with the antidrug antibody-informed approach. Additionally, many assays, some having significant limitations, have been used in studies; antidrug antibody threshold values that are informative for discriminating treatment responses have not been established. The evidence is insufficient to determine the effects of the technology on health outcomes.

SUPPLEMENTAL INFORMATION

Practice Guidelines and Position Statements

American College of Gastroenterology Institute

In 2017, the American College of Gastroenterology Institute published guidelines on therapeutic drug monitoring in inflammatory bowel disease.²⁹ The guidelines note that

"When anti-drug antibodies are detected, it is unclear what antibody level is clinically meaningful.... the reporting of anti-drug antibodies is variable between commercial assays, with some assays being very sensitive for detecting very-low-titer antibodies of limited clinical significance. Uniform thresholds for clinically relevant antibody titers are lacking. At this time, it is unclear how antibodies affect drug efficacy when both active drug and antibodies are detected. In cases of low trough concentrations and low or high anti-drug antibodies, the evidence to clarify optimal management is lacking."

The guidelines did not address therapeutic drug monitoring in patients treated with vedolizumab or ustekinumab.

National Institute for Health and Care Excellence

In 2016, the National Institute for Health and Care Excellence issued guidance on therapeutic monitoring of tumor necrosis factor α inhibitors in the treatment of patients with Crohn disease.³⁰ The Institute recommended that laboratories monitoring tumor necrosis factor α inhibitors in patients with Crohn disease who have lost response to the treatment should "work with clinicians to collect data through a prospective study, for local audit, or for submission to an existing registry."

U.S. Preventive Services Task Force Recommendations

Not applicable.

Medicare National Coverage

There is no national coverage determination. In the absence of a national coverage determination, coverage decisions are left to the discretion of local Medicare carriers.

REFERENCES

1. Bendtzen K. Personalized medicine: theranostics (therapeutics diagnostics) essential for rational use of tumor necrosis factor- α antagonists. *Discov Med*. Apr 2013; 15(83): 201-11. PMID 23636137
2. Kopylov U, Mazor Y, Yavzori M, et al. Clinical utility of antihuman lambda chain-based enzyme-linked immunosorbent assay (ELISA) versus double antigen ELISA for the detection of anti-infliximab antibodies. *Inflamm Bowel Dis*. Sep 2012; 18(9): 1628-33. PMID 22038899

The policies contained in the FEP Medical Policy Manual are developed to assist in administering contractual benefits and do not constitute medical advice. They are not intended to replace or substitute for the independent medical judgment of a practitioner or other health care professional in the treatment of an individual member. The Blue Cross and Blue Shield Association does not intend by the FEP Medical Policy Manual, or by any particular medical policy, to recommend, advocate, encourage or discourage any particular medical technologies. Medical decisions relative to medical technologies are to be made strictly by members/patients in consultation with their health care providers. The conclusion that a particular service or supply is medically necessary does not constitute a representation or warranty that the Blue Cross and Blue Shield Service Benefit Plan covers (or pays for) this service or supply for a particular member.

3. White CM, Ip S, McPheeters M, et al. Using Existing Systematic Reviews to Replace De Novo Processes in Conducting Comparative Effectiveness Reviews Methods Guide for Effectiveness and Comparative Effectiveness Reviews. Rockville, MD: Agency for Healthcare Research and Quality; 2009. <https://www.ncbi.nlm.nih.gov/books/NBK47094/>. Accessed October 13, 2020.
4. Meroni PL, Valentini G, Ayala F, et al. New strategies to address the pharmacodynamics and pharmacokinetics of tumor necrosis factor (TNF) inhibitors: A systematic analysis. *Autoimmun Rev*. Sep 2015; 14(9): 812-29. PMID 25985765
5. Garces S, Demengeot J, Benito-Garcia E. The immunogenicity of anti-TNF therapy in immune-mediated inflammatory diseases: a systematic review of the literature with a meta-analysis. *Ann Rheum Dis*. Dec 2013; 72(12): 1947-55. PMID 23223420
6. Lee LY, Sanderson JD, Irving PM. Anti-infliximab antibodies in inflammatory bowel disease: prevalence, infusion reactions, immunosuppression and response, a meta-analysis. *Eur J Gastroenterol Hepatol*. Sep 2012; 24(9): 1078-85. PMID 22647738
7. Nanda KS, Cheifetz AS, Moss AC. Impact of antibodies to infliximab on clinical outcomes and serum infliximab levels in patients with inflammatory bowel disease (IBD): a meta-analysis. *Am J Gastroenterol*. Jan 2013; 108(1): 40-7; quiz 48. PMID 23147525
8. Thomas SS, Borazan N, Barroso N, et al. Comparative Immunogenicity of TNF Inhibitors: Impact on Clinical Efficacy and Tolerability in the Management of Autoimmune Diseases. A Systematic Review and Meta-Analysis. *BioDrugs*. Aug 2015; 29(4): 241-58. PMID 26280210
9. Pecoraro V, De Santis E, Melegari A, et al. The impact of immunogenicity of TNF inhibitors in autoimmune inflammatory disease. A systematic review and meta-analysis. *Autoimmun Rev*. Jun 2017; 16(6): 564-575. PMID 28411169
10. Cludts I, Spinelli FR, Morello F, et al. Anti-therapeutic antibodies and their clinical impact in patients treated with the TNF antagonist adalimumab. *Cytokine*. Aug 2017; 96: 16-23. PMID 28279855
11. Ara-Martin M, Pinto PH, Pascual-Salcedo D. Impact of immunogenicity on response to anti-TNF therapy in moderate-to-severe plaque psoriasis: results of the PREDIR study. *J Dermatolog Treat*. Nov 2017; 28(7): 606-612. PMID 28274164
12. Lombardi G, Perego S, Sansoni V, et al. Anti-adalimumab antibodies in psoriasis: lack of clinical utility and laboratory evidence. *BMJ Open*. Dec 09 2016; 6(12): e011941. PMID 27940624
13. Arstikyte I, Kapleryte G, Butrimiene I, et al. Influence of Immunogenicity on the Efficacy of Long-Term Treatment with TNF Blockers in Rheumatoid Arthritis and Spondyloarthritis Patients. *Biomed Res Int*. 2015; 2015: 604872. PMID 26064930
14. van Gestel AM, Prevoo ML, van 't Hof MA, et al. Development and validation of the European League Against Rheumatism response criteria for rheumatoid arthritis. Comparison with the preliminary American College of Rheumatology and the World Health Organization/International League Against Rheumatism Criteria. *Arthritis Rheum*. Jan 1996; 39(1): 34-40. PMID 8546736
15. Castillo-Gallego C, Aydin SZ, Marzo-Ortega H. Clinical utility of the new ASAS criteria for spondyloarthritis and the disease activity score. *Curr Rheumatol Rep*. Oct 2011; 13(5): 395-401. PMID 21748416
16. Jani M, Chinoy H, Warren RB, et al. Clinical utility of random anti-tumor necrosis factor drug-level testing and measurement of antidrug antibodies on the long-term treatment response in rheumatoid arthritis. *Arthritis Rheumatol*. May 2015; 67(8): 2011-9. PMID 26109489
17. Frederiksen MT, Ainsworth MA, Brynskov J, et al. Antibodies against infliximab are associated with de novo development of antibodies to adalimumab and therapeutic failure in infliximab-to-adalimumab switchers with IBD. *Inflamm Bowel Dis*. Oct 2014; 20(10): 1714-21. PMID 25069030
18. Vande Castele N, Gils A, Singh S, et al. Antibody response to infliximab and its impact on pharmacokinetics can be transient. *Am J Gastroenterol*. Jun 2013; 108(6): 962-71. PMID 23419382
19. Eser A, Primas C, Reinisch W. Drug monitoring of biologics in inflammatory bowel disease. *Curr Opin Gastroenterol*. Jul 2013; 29(4): 391-6. PMID 23703367
20. Khanna R, Sattin BD, Afif W, et al. Review article: a clinician's guide for therapeutic drug monitoring of infliximab in inflammatory bowel disease. *Aliment Pharmacol Ther*. Sep 2013; 38(5): 447-59. PMID 23848220
21. Lichtenstein GR. Comprehensive review: antitumor necrosis factor agents in inflammatory bowel disease and factors implicated in treatment response. *Therap Adv Gastroenterol*. Jul 2013; 6(4): 269-93. PMID 23814608
22. Garces S, Antunes M, Benito-Garcia E, et al. A preliminary algorithm introducing immunogenicity assessment in the management of patients with RA receiving tumour necrosis factor inhibitor therapies. *Ann Rheum Dis*. Jun 2014; 73(6): 1138-43. PMID 23666932
23. Steenholdt C, Brynskov J, Thomsen OO, et al. Individualised therapy is more cost-effective than dose intensification in patients with Crohn's disease who lose response to anti-TNF treatment: a randomised, controlled trial. *Gut*. Jun 2014; 63(6): 919-27. PMID 23878167
24. Steenholdt C, Bendtzen K, Brynskov J, et al. Cut-off levels and diagnostic accuracy of infliximab trough levels and anti-infliximab antibodies in Crohn's disease. *Scand J Gastroenterol*. Mar 2011; 46(3): 310-8. PMID 21087119
25. Tan M. Importance of defining loss of response before therapeutic drug monitoring. *Gut*. Mar 2015; 64(3): 516-7. PMID 25031226
26. Roblin X, Rinaudo M, Del Tedesco E, et al. Development of an algorithm incorporating pharmacokinetics of adalimumab in inflammatory bowel diseases. *Am J Gastroenterol*. Aug 2014; 109(8): 1250-6. PMID 24913041

The policies contained in the FEP Medical Policy Manual are developed to assist in administering contractual benefits and do not constitute medical advice. They are not intended to replace or substitute for the independent medical judgment of a practitioner or other health care professional in the treatment of an individual member. The Blue Cross and Blue Shield Association does not intend by the FEP Medical Policy Manual, or by any particular medical policy, to recommend, advocate, encourage or discourage any particular medical technologies. Medical decisions relative to medical technologies are to be made strictly by members/patients in consultation with their health care providers. The conclusion that a particular service or supply is medically necessary does not constitute a representation or warranty that the Blue Cross and Blue Shield Service Benefit Plan covers (or pays for) this service or supply for a particular member.

27. Roblin X, Marotte H, Rinaudo M, et al. Association between pharmacokinetics of adalimumab and mucosal healing in patients with inflammatory bowel diseases. *Clin Gastroenterol Hepatol*. Jan 2014; 12(1): 80-84.e2. PMID 23891927
28. Afif W, Loftus EV, Faubion WA, et al. Clinical utility of measuring infliximab and human anti-chimeric antibody concentrations in patients with inflammatory bowel disease. *Am J Gastroenterol*. May 2010; 105(5): 1133-9. PMID 20145610
29. Feuerstein JD, Nguyen GC, Kupfer SS, et al. American Gastroenterological Association Institute Guideline on Therapeutic Drug Monitoring in Inflammatory Bowel Disease. *Gastroenterology*. Sep 2017; 153(3): 827-834. PMID 28780013
30. National Institute for Health and Care Excellence (NICE). Therapeutic monitoring of TNF-alpha inhibitors in Crohn's disease (LISA-TRACKER ELISA kits, IDKmonitor ELISA kits, and Promonitor ELISA kits) [DG22]. 2016; <https://www.nice.org.uk/guidance/dg22/chapter/1-Recommendations>. Accessed October 13, 2020.

POLICY HISTORY - THIS POLICY WAS APPROVED BY THE FEP® PHARMACY AND MEDICAL POLICY COMMITTEE ACCORDING TO THE HISTORY BELOW:

Date	Action	Description
December 2013	New policy	
December 2014	Replace policy	Policy updated with literature review. References 4-5, 15-18, 22, and 25-30 added. No changed to policy statements.
March 2017	Replace policy	Policy updated with literature review through November 3, 2016; references 4 and 33 added. Policy statements unchanged.
March 2018	Replace policy	Policy updated with literature review through September 11, 2017; references 14 and 21-23 added. Policy statements unchanged.
March 2019	Replace policy	Policy updated with literature review through September 6, 2018; reference 29 added. Policy statements unchanged.
March 2020	Replace policy	Policy updated with literature review through November 12, 2019; no references added. Investigational policy statement reworded to include newer TNF blocking agents; statement added in Policy Guideline section listing currently FDA-approved TNF blocking agents. Policy title changed to "Measurement of Serum Antibodies to Selected Biologic Agents".
March 2021	Replace policy	Policy updated with literature review through October 13, 2020; no references added. Updated terminology throughout the policy to reflect the addition of the interleukin-2 and -23 antagonist ustekinumab. Policy statement otherwise unchanged.

The policies contained in the FEP Medical Policy Manual are developed to assist in administering contractual benefits and do not constitute medical advice. They are not intended to replace or substitute for the independent medical judgment of a practitioner or other health care professional in the treatment of an individual member. The Blue Cross and Blue Shield Association does not intend by the FEP Medical Policy Manual, or by any particular medical policy, to recommend, advocate, encourage or discourage any particular medical technologies. Medical decisions relative to medical technologies are to be made strictly by members/patients in consultation with their health care providers. The conclusion that a particular service or supply is medically necessary does not constitute a representation or warranty that the Blue Cross and Blue Shield Service Benefit Plan covers (or pays for) this service or supply for a particular member.